| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5652 | zm-230487 | 5-Lipoxygenase (5-LO) inhibitor |
|
| DCC5653 | Zm-244085 | K-Channel opener (PCO) activating predominantly KATP channels in vitro to relax bladder detrusors |
|
| DCC5654 | zm-253270 | Selective nonpeptide, NK-2 receptor (NK-2R) antagonist |
|
| DCC5655 | Zm-260384 | Potassium channel opener |
|
| DCC5656 | Zm39923 Hydrochloride | Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3) |
|
| DCC5657 | Zn-htsm | Novel antidiabetic agent for the treatment of type 2 diabetes mellitus (DM) |
|
| DCC5658 | Zofenoprilat | Inducer of functional angiogenesis through increased H 2 S availability |
|
| DCC5659 | Zolantidine Dimaleate | Potent, selective, and brain penetrating H2 receptor antagonist |
|
| DCC5660 | Zoledronate Disodium | Inhibitor of osteoclastogenesis and macrophage recruitment, decreasing bone turnover and stabilizing the bone matrix, exhibiting diverse anti-tumor effects in osteosarcoma |
|
| DCC5661 | Zolimidine | Gastroprotective agent for the treatment of peptic ulcer |
|
| DCC5662 | Zp1-12cl | Novel zinc sensor with a chloroalkane linker, reacting specifically with the engineered protein HaloTag, binding zinc ions with a threefold fluorescence enhancement |
|
| DCC5663 | Ztb23(r) | The first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor |
|
| DCC5664 | Ztz240 | Novel potentiator of KCNQ2 potassium channels |
|
| DCC5665 | Zu-4280011 | Novel COX-2 inhibitor |
|
| DCC5666 | Zuclopenthixol Dihydrochloride | Antagonist of D1 and D2 dopamine receptors. |
|
| DCC5667 | Z-wehd-fmk | Potent, cell-permeable and irreversible caspase-1/5 inhibitor |
|
| DCC5668 | Zwittermicin A | Natural antibiotic, having diverse biological activities including broad-spectrum antibiosis against Bacteria and lower Eukarya, plant disease suppression, and enhancement of the insecticidal activity of Bacillus thuringiensis toxin against lepidopteran l |
|
| DCC5669 | Zwm026 | Novel multi-target inhibitor, harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR |
|
| DCC5670 | Zxh-1-161 Featured | Novel Selective Degrader of GSPT1 |
|
| DCC5671 | Zx-j-19j | Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil |
|
| DCC5672 | Zx-j-19l | Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil |
|
| DCC5673 | Zxx2-77 | Cyclooxygenase-1 inhibitor |
|
| DCC5674 | Zydpla1 | Novel next generation orally active DPP-4 inhibitor to treat Type 2 Diabetes |
|
| DCC5675 | Zyj-25e | Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities |
|
| DCC5676 | Zyj-34c | Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities |
|
| DCC5677 | Zyj-34v | Oral active histone deacetylase inhibitor with potent antitumor activity |
|
| DCC5678 | Zyz-803 | Novel slow H2S-NO-releasing hybrid, attenuating cardiac dysfunction after heart failure |
|
| DC73867 | EN171 Featured | EN171 covalently targets both C38 and C96 on 14−3−3 to enhance 14−3−3 interactions with ERα, YAP, and TAZ, leading to impaired estrogen receptor and Hippo pathway transcriptional activity. |
|
| DC73868 | CNB-001 | CNB-001 is a pyrazole derivative of curcumin with neuroprotective properties, inhibits extracellular Aβ toxicity in hippocampal neurons with EC50 of 400 nM. |
|
| DC73869 | DDQ | DDQ is a small molecule inhibitor of binding sites of Amyloid beta (Aβ) and Drp1, reduces interaction between Aβ and Drp1, shows anti-aging effects. |
|
